Bioinformatics and Experimental Insights Into <scp>miR</scp>‐182, hsa_circ_0070269, and circ‐102,166 as Therapeutic Targets for <scp>HCV</scp>‐Associated <scp>HCC</scp>
Our data revealed that miR-182 acts as an oncomiRNA in HCC development. Hsa_circ_0070269 and circ-102,166 are highly expressed in healthy controls compared to HCV induced HCC patients, can sponge miR-182 expression by acting as tumor suppressors, and can be used as biomarkers and targets for HCC treatment.
Authors
- Yasmeen Ishaq
- Hasnain Javed (ORCID: https://orcid.org/0000-0001-6877-6807)
- Imran Ho Abdullah (ORCID: https://orcid.org/0000-0003-0909-1802)
- Aqsa Ikram (ORCID: https://orcid.org/0000-0001-7292-6134)
- Bisma Rauff (ORCID: https://orcid.org/0000-0001-8302-9842)
- Badr Alzahrani (ORCID: https://orcid.org/0000-0003-4158-640X)
- Ghulam Mujtaba (ORCID: https://orcid.org/0000-0001-9244-5346)
Institutions
- University of Lahore (PK)
- University of Engineering and Technology Lahore (PK)
- Jouf University (SA)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cnr2.70049
- Primary Topic
- Circular RNAs in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00